Connect with us

Bussiness

FDA advisors recommend Eli Lilly’s Alzheimer’s drug donanemab, paving way for approval

Published

on

Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly & Co.’s shares climbed in early US trading after its experimental drug for Alzheimer’s slowed the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval.

AJ Mast | Bloomberg | Getty Images

Continue Reading